Immunovant’s batoclimab (FcRn inhibition) failed to meet primary endpoints in two Phase 3 trials in thyroid eye disease, with Roivant signaling it will review future development plans with partner HanAll. The failure marks another setback for IgG-suppression strategies in TED and follows prior decisions to limit commercialization plans in similar indications. Separately, Gilead terminated a Phase 2/3 trial of long-acting HIV pill candidates while an FDA clinical hold remains in place for the broader program. Gilead said the decision reflected discontinuation of safety follow-up for the Wonders-2 study, while Wonders-1 and related studies remain paused. For investors and trial planners, the pair of updates highlights the ongoing fragility of late-stage execution in immunology and the compliance-driven uncertainty still affecting long-acting HIV regimens.